Running Through Walls
Data-Driven Science and Leadership
AI Summary
In this episode, Dominik Schumacher, CEO and co‑founder of Tubulis GmbH, explains how the company’s antibody‑drug conjugate (ADC) technology uniquely targets cancer cells, minimizing side effects and enhancing patient outcomes. He details the distinctive chemistry that sets Tubulis’s ADCs apart from competitors and discusses the platform’s potential to treat other diseases beyond oncology. Schumacher also shares how a data‑driven approach has guided his transition from scientific research to executive leadership, enabling rapid, evidence‑based decision‑making across the business.
Episode Description
Dominik Schumacher, CEO and co-founder of Tubulis GmbH, joins Venrock's Nimish Shah to dive deeper on the company's ADC technology which specifically targets cancer cells thereby reducing side effects on the rest of the body, dramatically improving outcomes and quality of life for patients. They cover how their chemistry sets them apart from similar ADC treatments, what other diseases their breakthrough can target, and how staying data-driven helped him seamlessly move from the lab to leadership.
Show Notes
Dominik Schumacher, CEO and co-founder of Tubulis GmbH, joins Venrock's Nimish Shah to dive deeper on the company's ADC technology which specifically targets cancer cells thereby reducing side effects on the rest of the body, dramatically improving outcomes and quality of life for patients. They cover how their chemistry sets them apart from similar ADC treatments, what other diseases their breakthrough can target, and how staying data-driven helped him seamlessly move from the lab to leadership.
Comments
Want to join the conversation?
Loading comments...